Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

85 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Multilineage dysplasia is associated with a poorer prognosis in patients with de novo acute myeloid leukemia with intermediate-risk cytogenetics and wild-type NPM1.
Rozman M, Navarro JT, Arenillas L, Aventín A, Giménez T, Alonso E, Perea G, Camós M, Navarrete M, Tuset E, Florensa L, Millá F, Nomdedéu J, de la Banda E, Díaz-Beyá M, Pratcorona M, Garrido A, Navarro B, Brunet S, Sierra J, Esteve J; Grup Català de Citologia Hematològica and Spanish CETLAM Group (Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas Mieloblásticas). Rozman M, et al. Among authors: perea g. Ann Hematol. 2014 Oct;93(10):1695-703. doi: 10.1007/s00277-014-2100-6. Epub 2014 May 14. Ann Hematol. 2014. PMID: 24824767
Adverse prognostic impact of CD36 and CD2 expression in adult de novo acute myeloid leukemia patients.
Perea G, Domingo A, Villamor N, Palacios C, Juncà J, Torres P, Llorente A, Fernández C, Tormo M, Queipo de Llano MP, Bargay J, Gallart M, Florensa L, Vivancos P, Martí JM, Font L, Berlanga J, Esteve J, Bueno J, Ribera JM, Brunet S, Sierra J, Nomdedéu JF; CETLAM GroupSpain. Perea G, et al. Leuk Res. 2005 Oct;29(10):1109-16. doi: 10.1016/j.leukres.2005.02.015. Leuk Res. 2005. PMID: 16095690
Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)].
Perea G, Lasa A, Aventín A, Domingo A, Villamor N, Queipo de Llano MP, Llorente A, Juncà J, Palacios C, Fernández C, Gallart M, Font L, Tormo M, Florensa L, Bargay J, Martí JM, Vivancos P, Torres P, Berlanga JJ, Badell I, Brunet S, Sierra J, Nomdedéu JF; Grupo Cooperativo para el Estudio y Tratamiento de las Leucemias Agudas y Miel. Perea G, et al. Leukemia. 2006 Jan;20(1):87-94. doi: 10.1038/sj.leu.2404015. Leukemia. 2006. PMID: 16281071
Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia.
Monzo M, Brunet S, Urbano-Ispizua A, Navarro A, Perea G, Esteve J, Artells R, Granell M, Berlanga J, Ribera JM, Bueno J, Llorente A, Guardia R, Tormo M, Torres P, Nomdedéu JF, Montserrat E, Sierra J; CETLAM. Monzo M, et al. Among authors: perea g. Blood. 2006 Jun 15;107(12):4871-9. doi: 10.1182/blood-2005-08-3272. Epub 2006 Feb 28. Blood. 2006. PMID: 16507781 Free article. Clinical Trial.
Feasibility of the AML profiler (Skyline™ Array) for patient risk stratification in a multicentre trial: a preliminary comparison with the conventional approach.
Nomdedéu JF, Puigdecanet E, Bussaglia E, Hernández JJ, Carricondo M, Estivill C, Martí-Tutusaus JM, Tormo M, Zamora L, Serrano E, Perea G, de Llano MPQ, García A, Sánchez-Ortega I, Ribera JM, Nonell L, Aventin A, Solé F, Brunet MS, Sierra J. Nomdedéu JF, et al. Among authors: perea g. Hematol Oncol. 2017 Dec;35(4):778-788. doi: 10.1002/hon.2304. Epub 2016 May 3. Hematol Oncol. 2017. PMID: 27140599
85 results